Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant nivolumab or nivolumab + ipilimumab versus placebo after nephrectomy for high-risk localized renal cell carcinoma
jRCT2080223703Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Nivolumab + ipilimumab, Nivolumab and Placebo (3 arms). Started Nov 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on jRCT2080223703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223703.